SCHEMBL2277962

SCHEMBL2277962

CCCC(c1ccc(Cl)cc1)N(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.42
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SLC6A2 P23975 3/20 0.40
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 3/20 0.40
ADRB2 P07550 1/20 0.39
KAT2B Q92831 1/20 0.38
OPRM1 P35372 1/20 0.37
CHRM2 P08172 2/20 0.36
CHRM5 P08912 2/20 0.36
CHRM1 P11229 2/20 0.36
ADRA2B P18089 2/20 0.36
HRH2 P25021 2/20 0.36
HTR2A P28223 2/20 0.36
HRH1 P35367 2/20 0.36
KCNH2 Q12809 2/20 0.36
HRH3 Q9Y5N1 2/20 0.36
TSHR P16473 2/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19402470 0.83 AOC3 (0.44) AOC3LMNASMN1; SMN2SLC6A2SLC6A4
SCHEMBL4739377 0.82 AOC3 (0.44) AOC3LMNASMN1; SMN2SLC6A2SLC6A4
SCHEMBL6112111 0.82 AOC3 (0.44) AOC3LMNASMN1; SMN2SLC6A4SLC6A3
SCHEMBL21477341 0.80 ALDH1A1 (0.44) OPRM1TSHRL3MBTL1CHRNB2CHRNB4
SCHEMBL12513633 0.80 AOC3 (0.42) AOC3SLC6A2SLC6A4SLC6A3KAT2B
SCHEMBL4729602 0.79 AOC3 (0.42) AOC3LMNASMN1; SMN2SLC6A4SLC6A3
SCHEMBL2279691 0.79 AOC3 (0.42) AOC3LMNASMN1; SMN2SLC6A2SLC6A4
SCHEMBL11989946 0.79 CHRNB2 (0.53) AOC3LMNAOPRM1HTR2AHRH1
SCHEMBL19376998 0.78 NISCH (0.52) AOC3LMNASMN1; SMN2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL27689197 0.78 CHRNB2 (0.51) AOC3LMNASMN1; SMN2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994172-B2 [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism EXELIXIS, INC. (US) 2011-08-09 US disclosed
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases EXELIXIS, INC. (US) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases PDPK1, MTOR, RPS6KA2 AOC3 4746/4885LMNA 4117/4885SMN1; SMN2 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.